Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of SHR-1701 with or without famitinib malate in previously treated extensive-stage small cell lung cancer
CTR20211049Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- May 2021
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa, famitinib in small cell lung cancer (SCLC), sponsored by Hengrui Therapeutics. Started May 2021; status: active.
02
Drugs
retlirafusp alfafamitinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20211049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211049.